As in multiple myeloma, patients with systemic lupus, and healthy donors, NK cells decreased for 6 months, suggesting their sensitivity to daratumumab-mediated lysis, because CD38 is expressed in up to 70% of NK cells where it physically or functionally cluster with FcγRIII/CD16, a critical membrane molecule.27 This evidence concerns the gene CD38 and plasma cell myeloma.